Faculty
Kathy Weilbaecher.jpg

Katherine N. Weilbaecher, MD

Professor
Department of Medicine
Oncology Division
Molecular Oncology
Department of Cell Biology & Physiology
Department of Pathology & Immunology

Clinical Interests

  • Breast cancer
  • Bone metastasis

Research Interests

  • Skeletal metastasis
  • Beta 3 integrin
  • Osteoclast/macrophage biology
  • HTLV-1
  • Targeted nanotherapy

Contact

  • 314-454-8858 (tel)
  • 314-454-7086 (fax)
  • Room 806, McDonnell Sciences Building (office)
  • Washington University School of Medicine
    Division of Oncology
    Campus Box 8069
    660 South Euclid Avenue
    St. Louis, MO 63110

Invited Articles & Reviews

  • Contact-Facilitated Drug Delivery With Sn2 Lipase Labile Prodrugs Optimize Targeted Lipid Nanoparticle Drug Delivery
    Pan D, Pham CT, Weilbaecher KN, Tomasson MH, Wickline SA, Lanza GM
    Wiley Interdiscip Rev Nanomed Nanobiotechnol 2016 Jan;8(1):85-106
  • Together - Every Woman's Guide to Preventing Breast Cancer
    Colditz G, Dart H, Weilbaecher K
    E-Book. https://itunes.apple.com/us/book/together-every-womans-guide/id1020301603?mt=11
  • Hedgehog-Targeted Therapeutics Uncouple the Vicious Cycle of Bone Metastasis
    Hurchla MA, Weilbaecher KN
    Oncoimmunology 2012 Nov 1;1(8):1411-13
  • Cancer to Bone: A Fatal Attraction
    Weilbaecher KN, Guise TA, McCauley LK
    Nat Rev Cancer 2011 Jun;11(6):411-25
  • Integrins and Bone Metastasis: Integrating Tumor Cell and Stromal Cell Interactions
    Schneider JG, Amend SR, Weilbaecher KN
    Bone 2011 Jan 1;48(1):54-65
  • The CXCR4/SDF-1 Chemokine Axis: A Potential Therapeutic Target for Bone Metastases?
    Hirbe AC, Morgan EA, Weilbaecher KN
    Curr Pharm Des 2010;16(11):1284-90
  • Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations From the Second Cambridge Conference
    Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, Weilbaecher KN
    Clin Cancer Res 2008 Oct 15;14(20):6387-95
  • Aromatase Inhibitors and Bone Loss
    Perez EA, Weilbaecher K
    Oncology (Williston Park) 2006 Aug;20(9):1029-39; discussion 1039-40
  • Advances in Treating Metastatic Bone Cancer: Summary Statement for the First Cambridge Conference
    Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King L
    Clin Cancer Res 2006 Oct 15;12(20 Pt 2):6209s-6212s
  • Skeletal Complications of Breast Cancer Therapies
    Hirbe A, Morgan EA, Uluckan O, Weilbaecher K
    Clin Cancer Res 2006 Oct 15;12(20 Pt 2):6309s-6314s
  • Skeletal Complications of Breast and Prostate Cancer Therapies
    Hirbe A, Morgan E, Uluckan O, Weilbaecher K
    In: Favus MJ (ed), Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 6th ed., ASBMR, Washington, DC, USA, pp 390-395 (2006)
  • Third North American Symposium on Skeletal Complications of Malignancy: Summary of the Scientific Sessions
    Mohla S, Weilbaecher KN, Cher M, Oyajobi B, Van Poznak C, and D Clohisy
    Cancer 2003; 97(3 Supplement):719-725
  • Mechanisms of Osteoporosis After Hematopoietic Cell Transplantation
    Weilbaecher KN
    Biol Blood Marrow Transplant 2000;6(2A):165-74